News

BioSpace3d
Sarepta Fallout Continues With EU’s Negative Opinion of Elevidys in Ambulatory Patients
The European Union’s health regulatory agency did not endorse approving Elevidys for ambulatory patients with Duchenne ...
Fierce Pharma3d
Roche won't throw in the towel after DMD gene therapy Elevidys' rebuff in Europe
Despite a new setback for Elevidys in Europe, Roche—which markets Sarepta’s gene therapy outside the U.S.—remains committed ...
Investing.com South Africa3d
Sarepta stock falls after Elevidys fails to get backing by EU regulators
The European Medicines Agency’s drug advisory committee (CHMP) rejected Elevidys for children aged 3 to 7 years who are able ...
Yahoo Finance3mon
Sarepta Therapeutics Provides Update on ELEVIDYS - Yahoo Finance
CAMBRIDGE, Mass., April 04, 2025--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, shared the following update related to ELEVIDYS ...
Seeking Alpha2mon
Sarepta: ELEVIDYS DMD Treatment Setback Brings Downgrade To Hold Rating
Sarepta: ELEVIDYS DMD Treatment Setback Brings Downgrade To Hold Rating. May 07, 2025 2:14 PM ET Sarepta Therapeutics, Inc. (SRPT) Stock NVS, ARWR, NVS:CA, NVSEF, SRPT 15 Comments 1 Like.
Business Insider3mon
Sarepta announces EU regulators temporarily halted dosing of ELEVIDYS
Sarepta (SRPT) Therapeutics shared the following update related to ELEVIDYS, the only approved gene therapy in patients with Duchenne muscular dystrophy. Following the safety update on acute liver ...
Business Wire3mon
Sarepta Therapeutics Provides Update on ELEVIDYS - Business Wire
Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, shared the following update related to ELEVIDYS (deland ...
Seeking Alpha1y
Sarepta Therapeutics: Navigating Elevidys Upside Potential
Under this agreement, Roche and Sarepta share the Research & Development cost associated with obtaining and maintaining regulatory approvals for Elevidys in the U.S. and the EU. As reported in ...